Interventions for erythema nodosum leprosum

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Van Veen, Natasja H J ^a   Lockwood, D N J ^b   Van Brakel, W H ^b   Ramirez Jr , J ^b   Richardus, J H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETAMETHASONE; CHLOROQUINE; CLOFAZIMINE; COLCHICINE; CYCLOSPORIN A; INDOMETACIN; METHYLPREDNISOLONE; MYCOBACTERIUM VACCINE; PENTOXIFYLLINE; PREDNISOLONE; THALIDOMIDE; ZINC;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 44949144024     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006949     Document Type: Review

References (24)

1. Heijnders 2004 Heijnders ML. The dynamics of stigma in leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 2004;72(4):437-47.
2. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2005.
3. ILEP 1996 The International Federation of Anti-Leprosy Associations (ILEP). The management of erythema nodosum leprosum. ILEP Technical Bulletin 1996, issue 9.
4. ILEP 2001 The International Federation of Anti-Leprosy Associations (ILEP). How to diagnose and treat leprosy. London: ILEP, 2001.
5. ILEP 2002 The International Federation of Anti-Leprosy Associations (ILEP). How to recognise and manage reactions. London: ILEP, 2002.
6. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
7. Kumar 2004 Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. International Journal of Leprosy and Other Mycobacterial Diseases 2004;72(2):125-33.
8. Lockwood 1996 Lockwood DN. The management of erythema nodosum leprosum: current and future options. Leprosy Review 1996;67(4): 253-9.
9. Mahajan 1994 Mahajan PM, Jadhav VH, Patki AH, Jogaikar DG, Mehta JM. Oral zinc therapy in recurrent erythema nodosum leprosum: a clinical study. Indian Journal of Leprosy 1994;66(1):51-7.
10. Manandhar 1999 Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. International Journal of Leprosy and Other Mycobacterial Diseases 1999;67(3):270-8.
11. Naafs 2003a Naafs B. Reactions: the body as battlefield I: clinical aspects. Memisa Medisch 2003;69(2):330-6.
12. Naafs 2003b Naafs B. Reactions: the body as battlefield II: immunopathology. Memisa Medisch 2003;69(2):337-42.
13. Nery 1998 Nery JA, Vieira LM, de Matos HJ, Gallo ME, Sarno EN. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Revista do Instituto de Medicina Tropical de São Paulo 1998;40(6):363-70.
14. Nery 2000 Nery JA, Perisse AR, Sales AM, Vieira LM, Souza RV, Sampaio EP, et al.The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian Journal of Leprosy 2000;72(4):457-67.
15. Pocaterra 2006 Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al.Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. American Journal of Tropical Medicine and Hygiene 2006;74(5):868-79.
16. Rafferty 2005 Rafferty J. Curing the stigma of leprosy. Leprosy Review 2005;76(2):119-26.
17. Saunderson 2000 Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Leprosy Review 2000;71(3):318-24.
18. Smith 2002 Smith WC, Nicholls PG. Special workshop on repeated and late reactions. International Journal of Leprosy and Other Mycobacterial Diseases 2002;70(4):339-41.
19. Uyemura 1986 Uyemura K, Dixon JF, Wong L, Rea TH, Modlin RL. Effect of cyclosporine A in erythema nodosum leprosum. Journal of Immunology 1986;137(11):3620-3.
20. Van Brakel 2005 van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al.The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Leprosy Review 2005;76(1):277-95.
21. WHO 2003 World Health Organization. WHO Guidelines for the management of severe erythema nodosum leprosum (ENL) reactions. World Health Organization 2003.
22. WHO 2006a World Health Organization. Leprosy. http://www.who.int/ mediacentre/factsheets/fs101/en/index.html (Accessed 27 November 2006).
23. WHO 2006b World Health Organization. Global leprosy situation, 2006. Weekly Epidemiological Record 2006;81(32):309-16.
24. Zaheer 1993 Zaheer SA, Misra RS, Sharma AK, Beena KR, Kar HK, Mukherjee A, et al.Immunotherapy with Mycobacterium w vaccine decreases the incidence and severity of type 2 (ENL) reactions. Leprosy Review 1993;64(1):7-14.